Aware Super Pty Ltd as trustee of Aware Super Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,670 shares of the company's stock, valued at approximately $2,139,000.

A number of other institutional investors also recently bought and sold shares of NBIX. Caprock Group LLC purchased a new position in Neurocrine Biosciences in the 4th quarter valued at about $236,000. Charles Schwab Investment Management Inc. increased its holdings in Neurocrine Biosciences by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock valued at $104,089,000 after purchasing an additional 15,266 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in Neurocrine Biosciences during the 3rd quarter worth approximately $3,236,000. Oakworth Capital Inc. acquired a new stake in Neurocrine Biosciences during the 4th quarter valued at $379,000. Finally, Synergy Asset Management LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $996,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on NBIX shares. Wedbush decreased their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Morgan Stanley reissued an "overweight" rating and set a $150.00 target price (down from $185.00) on shares of Neurocrine Biosciences in a research note on Friday, March 7th. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 26th. William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Finally, Needham & Company LLC raised Neurocrine Biosciences from a "hold" rating to a "buy" rating and set a $138.00 price objective on the stock in a report on Tuesday. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and an average price target of $161.86.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the transaction, the director now owns 517,030 shares of the company's stock, valued at $79,064,227.60. This represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matt Abernethy sold 2,558 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total transaction of $298,927.88. Following the completion of the sale, the chief financial officer now owns 34,775 shares in the company, valued at $4,063,806.50. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 167,906 shares of company stock worth $24,671,530. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Up 1.3 %

Shares of NASDAQ NBIX traded up $1.28 on Friday, reaching $101.38. 1,926,795 shares of the company's stock traded hands, compared to its average volume of 1,053,158. The business's 50 day simple moving average is $108.66 and its two-hundred day simple moving average is $122.48. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $157.98. The company has a market cap of $10.03 billion, a price-to-earnings ratio of 30.81, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has initiated a stock buyback program on Friday, February 21st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.